NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Forecast & News

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals Inc (NASDAQ:CNCE) announced its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.86) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.07. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.08 million. Concert Pharmaceuticals had a negative net margin of 7,291.37% and a negative return on equity of 55.06%. View Concert Pharmaceuticals' Earnings History.

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Concert Pharmaceuticals.

7 Wall Street analysts have issued 12 month price targets for Concert Pharmaceuticals' shares. Their forecasts range from $10.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $18.14 in the next year. This suggests a possible upside of 114.5% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

News coverage about CNCE stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Concert Pharmaceuticals.

Concert Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 618,700 shares, an increase of 5.1% from the January 30th total of 588,400 shares. Based on an average trading volume of 209,800 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.9% of the shares of the company are sold short. View Concert Pharmaceuticals' Current Options Chain.

Some companies that are related to Concert Pharmaceuticals include Zogenix (ZGNX), Amneal Pharmaceuticals (AMRX), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Phibro Animal Health (PAHC), Revance Therapeutics (RVNC), Dermira (DERM), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Athenex (ATNX), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT) and Portola Pharmaceuticals (PTLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Lexicon Pharmaceuticals (LXRX) and Cidara Therapeutics (CDTX).

Concert Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (7.27%), Bank of America Corp DE (6.05%), Ingalls & Snyder LLC (6.15%), Renaissance Technologies LLC (2.14%), State Street Corp (1.38%) and Prudential Financial Inc. (1.24%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss. View Institutional Ownership Trends for Concert Pharmaceuticals.

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Russell Investments Group Ltd., Perceptive Advisors LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Prudential Financial Inc., New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.

CNCE stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Alyeska Investment Group L.P., Jacobs Levy Equity Management Inc., Panagora Asset Management Inc., Alambic Investment Management L.P., Oxford Asset Management LLP, Geode Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNCE stock can currently be purchased for approximately $8.46.

Concert Pharmaceuticals has a market capitalization of $250.21 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]